Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
about
Targeting the insulin growth factor receptor 1Insulin-like Growth Factor 1 Signaling Axis Meets p53 Genome Protection PathwaysThe adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapyEpitope-specific mechanisms of IGF1R inhibition by ganitumabInsulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potentialIGF-IR Targeted Therapy: Past, Present and FutureCausal Modeling of Cancer-Stromal Communication Identifies PAPPA as a Novel Stroma-Secreted Factor Activating NFκB Signaling in Hepatocellular CarcinomaVEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancerThe endoplasmic reticulum protein folding factory and its chaperones: new targets for drug discovery?Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathwayDefining the pathway to insulin-like growth factor system targeting in cancer.Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer modelErbB2 enhances mammary tumorigenesis, oncogene-independent recurrence and metastasis in a model of IGF-IR-mediated mammary tumorigenesis.Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients.Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibitionGeneration and screening of monoclonal antibodies for immunoPET imaging of IGF1R in prostate cancer.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulationInsulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Evaluation of a novel hexavalent humanized anti-IGF-1R antibody and its bivalent parental IgG in diverse cancer cell linesAntitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.Protein secretion is required for pregnancy-associated plasma protein-A to promote lung cancer growth in vivo.Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF SignalSuccinate dehydrogenase-deficient gastrointestinal stromal tumors.Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and ExpectationsExpression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancerQuantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.Genetic reduction of insulin-like growth factor-1 mimics the anticancer effects of calorie restriction on cyclooxygenase-2-driven pancreatic neoplasia.Case series of dermatologic events associated with the insulin-like growth factor receptor 1 inhibitor cixutumumab.OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activitySquamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.
P2860
Q24633750-4E8AFE67-0B45-4484-85B4-FC548BE82CBDQ26742114-571D63C6-27B6-4040-81F2-C01065778A5DQ27000467-4A61552E-ABF9-4E92-A149-BB9133121442Q27317385-F678FB8E-DEFF-4059-9A55-46B210607208Q27852235-F9F1B58F-2523-408B-9420-F7AF0CB45BE3Q28075927-BFF18438-4417-40C4-B84B-73520E103C8BQ28082127-2B2F54A2-94B5-4010-933B-B2BC34AC5A78Q28547556-E96075FF-2484-49FC-ACD7-54E57577F988Q30595149-0D5CF7F0-11CC-46B2-AE17-43498B6CB53EQ33717397-C195B2E9-74B4-47AF-B6A3-0DB99C73A7F7Q33796176-1B98EE78-FE33-4106-9A09-D7B1214F2FD6Q33934670-FC4C5C26-6903-4EAB-AFFD-A1EB646133BBQ34023553-CCFCF03E-0D23-4626-B34A-17F4A3E4A1C9Q34107722-4206D915-A46A-4042-B1B3-DE28A38FE207Q34123598-16C01E5E-C752-4382-8A0F-B169C0942477Q34133760-AFDD2D56-0321-4016-AFDA-528489BE8A9BQ34180248-CE274F75-3CE8-4256-9B1B-CD2E3800439AQ34186221-51EA2A1E-4BE2-41FF-BB16-F32CFD0F563FQ34187898-0D1ACFE3-01CB-46DF-B911-D8F024884AC8Q34293602-EB5FFB2A-C332-4A15-BC1C-E4ACDE97CAC7Q34336988-1290489D-4A60-4CC1-A54B-8A2268216977Q34387886-6D956471-F178-4CAB-B6EA-3FBCA30FB237Q34391968-2D37AD62-ECF9-4B55-AD17-1A9DE10173BEQ34406479-730C0584-C18D-442C-BA9A-22F4CABC6F89Q34431333-ED7717F9-0172-4321-8CBC-AE883ECA1072Q34477488-457DB6DD-2936-488C-AACA-49C7502D8CC0Q34577559-891B9703-D011-4820-95DB-21958EDCF587Q34647501-87B34323-DBFD-49B4-9D2B-F3A3953FA76CQ34668378-1AF050AC-5704-4140-BAC4-DF34473A4B60Q34683782-3FB35365-76ED-435F-959F-835EA73B8828Q35013284-5D3CB55F-AE74-488C-BF5F-FC49B1E81731Q35018535-FE1C2315-4586-4FC5-91C8-4A32FD15455AQ35030616-EF82AE13-0243-438E-AC67-5500E3D4C37EQ35044404-3D1F76AE-4A83-4719-B5E7-7810E159CA0EQ35070321-2FC941C5-89BB-4937-BA76-310CE6ACC739Q35091299-28565D2A-AD2A-4373-B35D-BD8D31E57BE2Q35112345-23DE0167-8BEA-4163-9200-5060B004F09EQ35131269-A3FE253B-F758-458F-9C1D-8488BB2AE898Q35146077-C1969EB3-82B4-43B8-9AEA-6CDA43104EF2Q35220347-D691DF2E-C6BE-49E8-8664-D1310E30F7FA
P2860
Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging role of insulin-like ...... results and future directions.
@en
Emerging role of insulin-like ...... results and future directions.
@nl
type
label
Emerging role of insulin-like ...... results and future directions.
@en
Emerging role of insulin-like ...... results and future directions.
@nl
prefLabel
Emerging role of insulin-like ...... results and future directions.
@en
Emerging role of insulin-like ...... results and future directions.
@nl
P356
P1433
P1476
Emerging role of insulin-like ...... results and future directions.
@en
P2093
P2888
P304
P356
10.1038/ONC.2009.172
P407
P577
2009-07-06T00:00:00Z